Amendments to the Claims:

1. (Cancel) Use of peptide antagonists at glutamate receptors for the manufacture of a medicament to influence the glutamate receptor-controlled cells.

2. (Withdrawn) Use of peptide antagonists at NMDA receptors for the manufacture of a medicament to influence the NMDA-receptor-controlled cells.

3. (Withdrawn) Use according to claim 2 in which the medicament prevents NMDA-receptor-mediated excitatory effects such as release of neurotransmitter or peptide as well as toxic effects resulting in cell injury or death.

4. (Withdrawn) Use according to any of claims 1 to 3 in which the cells are neurons or glial cells in the central nervous system.

5. (Withdrawn) Use according to any of claims 1 or 4 in which the medicament comprises glutamic acid-terminating peptides.

6. (Withdrawn) Use according to any of claims 1 to 5 in which the antagonist is chosen among (1-5) GnRH, (1-3) IGF-I, (1-37) GRF and C-peptide of insulin.

7. (Withdrawn) Use according to any of claims 1 to 6 in which the medicament influence GnRH secretion.

8. (Withdrawn) Use according to any of claims 1 to 7 for the treatment of acute or chronic disorders of the central nervous system.

9. (Withdrawn) Use according to any of claims 1 to 7 for the treatment of hypoxic, ischemic and metabolic brain disorders such as stroke and hypoglycaemia, traumatic, radiation-induced or inflammatory injuries to the brain and chronic degenerative states.

10. (Withdrawn) Use according to any of claims 1 to 9 for the treatment of children during the perinatal period and infancy.

11. (Withdrawn) Use according to any of claims 1 to 10 in which the medicament comprises (1-3) IGF-I.

12. (Withdrawn) Use according to any of claims 1 to 11 in which the medicament is administered systemically.

13. (Withdrawn) Use according to any of claims 1 to 11 in which the medicament is administered locally.

14. (Currently amended) The method ~~Method~~ for influencing ~~influence on~~ glutamate-receptor-controlled cells by administration of a peptide antagonist ~~antagonists~~ at glutamate receptors.

15. (Currently amended) A method ~~Method~~ for influencing ~~influence on~~ NMDA-receptor-controlled cells by administration of a peptide antagonist ~~antagonists~~ at NMDA receptors.

16. (Currently amended) The method ~~Method~~ according to claim 15 wherein said influence is to inhibit ~~for preventing~~ NMDA-receptor mediated excitatory effects selected from the group consisting of ~~such as~~ release of neurotransmitter or peptide and ~~as well as~~ toxic effects resulting in cell injury or death.

17. (Currently amended) The method ~~Method~~ according to any of claims 14 to 16 wherein said influence is to improve ~~for influence on the~~ function of neurons or glial cells in the central nervous system.

18. (Currently amended) The method ~~Method~~ according to any of claims 14 to 17 in which the ~~antagonists~~ antagonist at NMDA receptors comprises a glutamic acid-terminating ~~peptides~~ peptide.

19. (Currently amended) The method ~~Method~~ according to any of claims 14 to 18 in which the antagonist is chosen ~~among~~ from the group consisting of (1-5) GnRH, (1-3) IGF-I, (1-37) GRF and C-peptide of insulin.

20. (Currently amended) The method ~~Method~~ according to any of claim 14 to 19 for influencing the GnRH secretion.

21. (Currently amended) The method ~~Method~~ according to any of claims 14 to ~~120~~ 20 for the treatment of acute or chronic disorders of the central nervous system.

22. (Currently amended) The method ~~Method~~ according to any of claims 14 to ~~20~~ 21 for the treatment of at least one of hypoxic, ischemic and metabolic brain disorders, ~~such as~~ stroke, ~~and~~ hypoglycaemia, traumatic, radiation-induced or inflammatory injuries to the brain and chronic degenerative states.

23. (Currently amended) The method ~~Method~~ according to any of claims 14 to 21 for the treatment of children during the perinatal period and infancy.

24. (Currently amended) The method ~~Method~~ according to any of claims 14 to 22 in which a medicament is administered which comprises the C-peptide of insulin ~~(1-3) IGF-I~~.

25. (Currently amended) The method ~~Method~~ according to any of claims 14 to ~~23~~ 24 in which a medicament is administered systemically.

26. (Currently amended) The method ~~Method~~ according to any of claims 14 to ~~23~~ 24 in which a medicament is administered locally.

27. (Currently amended) The method of Claim 14 ~~Method~~ for the treatment of a brain condition associated with receptor-mediated excitatory effects, selected from the group consisting of hypoxic, ischemic, and metabolic brain disorders, brain injuries, and chronic degenerative brain states, comprising administering a peptide that acts as an antagonist of glutamate receptors in the central nervous system in an amount effective to prevent the excitatory effects.

28. (Currently amended) The method of claim 27 where the peptide is ~~(1-3)IGF-1~~ C-peptide of insulin.

29. (Original) The method of claim 27 where the condition is stroke.